Current Neuro-Oncology
Volume
26 Number 18
31 August 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 18, 31 August
Ghosh HS, Patel RV, Woodward E, Greenwald NF, Bhave VM, Maury EA,
Cello G, Hoffman SE, Li Y, Gupta H, Youssef G, Spurr LF, Vogelzang
J, Touat M, Dubois F, Cherniack AD, Guo X, Tavakol S, Cioffi G,
Lindeman NI, Ligon AH, Chiocca EA, Reardon DA, Wen PY, Meredith D,
Santagata S, Barnholtz-Sloan JS, Ligon KL, Beroukhim R, Bi WL.
Contemporary Prognostic Signatures and
Refined Risk Stratification of Gliomas: An Analysis of 4,400
Tumors.
Neuro
Oncol. 2024 Aug 21:noae164. doi:
10.1093/neuonc/noae164. PMID:
39164213. Observational study. ˍ
Ståhl P, Henoch I, Rydenhag B, Smits A, Ozanne A.
Living
with glioblastoma - the need for integrated support based on
experiences of chaos, loss of autonomy, and isolation in both
patients and their relatives.
Support
Care Cancer. 2024 Aug 21;32(9):599. doi:
10.1007/s00520-024-08801-y. PMID:
39167224. Observational study. ˍ
Wang JZ, Patil V, Landry AP, Gui C, Ajisebutu A, Liu J, Saarela O,
Pugh SL, Won M, Patel Z, Yakubov R, Kaloti R, Wilson C,
Cohen-Gadol A, Zaazoue MA, Tabatabai G, Tatagiba M, Behling F,
Almiron Bonnin DA, Holland EC, Kruser TJ, Barnholtz-Sloan JS,
Sloan AE, Horbinski C, Chotai S, Chambless LB, Gao A, Rebchuk AD,
Makarenko S, Yip S, Sahm F, Maas SLN, Tsang DS; International
Consortium on Meningiomas (ICOM); Rogers CL, Aldape K, Nassiri F,
Zadeh G.
Molecular classification to
refine surgical and radiotherapeutic decision-making in
meningioma.
Nat
Med. 2024 Aug 21. doi:
10.1038/s41591-024-03167-4. PMID:
39169220. Observational study. ˍ
Zhou WT, Niu JH, Liao C, Ren SK, Ou YW, Liu W, Li CD, Gong J, Tian
YJ.
Visual deterioration outcomes
following optic pathway glioma treatment: a 12-year single
institution retrospective study.
J
Neurooncol. 2024 Aug 21. doi:
10.1007/s11060-024-04802-3. PMID:
39167244. Observational study˰
ˍ
Hassan J, Hyde C, Joiner M, Miller SR.
Complete
radiographic response after proton radiation therapy in the
re-irradiation of a diffuse high-grade glioma: A case report.
SAGE
Open Med Case Rep. 2024 Aug 22;12:2050313X241274218.
doi:
10.1177/2050313X241274218. PMID:
39185065. Case report. ˍ
Zemskova O, Yu NY, Leppert J, Löser A, Rades D.
Can
Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte
Ratio (NLR) Help Predict Outcomes of Patients With Recurrent
Glioblastoma?
In
Vivo. 2024 Aug 26;38(5):2341-2348. doi:
10.21873/invivo.13700. PMID:
39187342. Observational study. ˍ
Hainfellner A, Borkovec M, Seebrecht L, Neuhauser M,
Roetzer-Pejrimovsky T, Greutter L, Surböck B, Hager-Seifert
A, Gorka-Vom Hof D, Urbanic-Purkart T, Stultschnig M, Cijan C,
Würtz F, Calabek-Wohinz B, Pichler J, Höllmüller I,
Leibetseder A, Weis S, Kleindienst W, Seiberl M, Bieler L, Hecker
C, Schwartz C, Iglseder S, Heugenhauser J, Nowosielski M, Thomé
C, Moser P, Hoffermann M, Loibnegger K, Dieckmann K, Tomschik M,
Widhalm G, Rössler K, Marosi C, Wöhrer A, Hainfellner
JA, Oberndorfer S.
Glioblastoma in the
real-world setting: patterns of care and outcome in the Austrian
population.
J
Neurooncol. 2024 Aug 27. doi:
10.1007/s11060-024-04808-x. PMID:
39192069. Observational study. ˍ
Cheng F, Lin HF, Liang XJ, Wu SY, Wu XF, Tu WF.
Evaluation
of Factors Influencing Postoperative Cognitive Dysfunction in
Patients After Cranial Tumor Surgery.
J Craniofac
Surg. 2024 Aug 28. doi:
10.1097/SCS.0000000000010546. PMID:
39194192. Observational study˰
ˍ
Gulino V, Brunasso L, Avallone C, Costa V, Adorno AA, Lombardo MC,
Tumbiolo S, Iacopino DG, Maugeri R.
Caregivers'
Perspective and Burden of The End-of-Life
Phase of Patients With Glioblastoma:
A Multicenter Retrospective Study.
World
Neurosurg. 2024 Aug
28:S1878-8750(24)01482-7. doi:
10.1016/j.wneu.2024.08.114. PMID:
39214291. Observational study. ˍ
*Watanabe T, Noto S, Natsumeda M, Kimura S, Ikarashi F, Tabata S,
Takano M, Tsukamoto Y, Oishi M.
Improvements
in activities of daily living among patients with brain tumors are
associated with age, baseline physical function, duration of
rehabilitation, and tumor recurrence but not type.
Int
J Rehabil Res. 2024 Aug 28. doi:
10.1097/MRR.0000000000000641. PMID:
39190364. Observational study˰
ˍ
Ledford A, Rodriguez A, Lipinski L, Abad A, Fenstermaker R,
Edenfield J, Kanos C, Redjal N, Mansouri A, Zacharia B, Butowski
N, Liu J, Han SJ, Ziu M, Cohen AL, Fabiano AJ, Miles K, Rayner M,
Thompson J, Tollison K, Azimzadeh P, Holmes L, Gevaert M,
DesRochers TM.
Functional prediction
of response to therapy prior
to therapeutic intervention is associated with improved survival
in patients
with high-grade glioma.
Sci
Rep. 2024 Aug 29;14(1):19474. doi:
10.1038/s41598-024-68801-0. PMID:
39198514. Observational study. ˍ
Aboubakr O, Moiraghi A, Elia A, Tauziede-Espariat A, Roux A,
Leclerc A, Planet M, Bedioui A, Simboli GA, Dhermain F, Parraga E,
Benevello C, Fathallah H, Muto J, Chrétien F, Dezamis E,
Oppenheim C, Varlet P, Zanello M, Pallud J.
Long-term
survivors in 976 supratentorial glioblastoma, IDH-wildtype
patients.
J
Neurosurg. 2024 Aug
30:1-13. doi:
10.3171/2024.5.JNS24393. PMID:
39213667. Observational study˰
ˍ
Bauman MMJ, Jusue-Torres I, White JJ, Bouchal SM, Hsu AR, Ha Y,
Pumford AD, Hong S, Riviere-Cazaux C, Wang K, Brown DA, Helal A,
Parney IF.
Presentation,
surgical outcome, and supplementary
motor area syndrome risk of posterior
superior frontal gyrus tumors.
J
Neurosurg. 2024 Aug 30:1-12. doi:
10.3171/2024.5.JNS231850. PMID:
39213666. Observational study˰
ˍ
Ferini G, Scalia G, Harikar M, Zagardo V, Castorina L, Comis A,
Boncoraglio A, Chaurasia B, Palmisciano P, Umana GE.
Comparative
Analysis of Recurrent Glioblastoma Target Contours via
11C-Methionine,
68Ga-Prostate-Specific
Membrane Antigen Positron Emission Tomography, and Magnetic
Resonance Imaging: Implications for Precision Radiotherapy
Planning.
Adv
Radiat Oncol. 2024 Jun 4;9(9):101548. doi:
10.1016/j.adro.2024.101548. PMID:
39188994. Case report. ˍ
Chintapalli R.
Physical Health-Related
Quality of Life and Postsurgical
Outcomes in Brain Tumor Resection
Patients.
Asian
J Neurosurg. 2024 Jun 10;19(3):412-418. doi:
10.1055/s-0044-1787674. PMID:
39205899. Observational study. ˍ
Al-Khatib SM, Al-Bzour AN, Almajali MN, Jarrad TA, Al-Eitan LN,
Abdo N.
Analysis of IDH and EGFR as
biomarkers in glioblastoma multiforme: A case-control study.
Heliyon.
2024 Jul 26;10(15):e35323. doi:
10.1016/j.heliyon.2024.e35323. PMID:
39165999. Observational study. ˍ
Goldlust SA, Singer S, Cappello LA, AlMekkawi AK, Lee KD, Ingenito
AC, Lewis BE, Nyirenda T, Azmi H, Kaptain GJ.
Phase
1 study of concomitant tumor treating fields and temozolomide
chemoradiation for newly diagnosed glioblastoma.
Neurooncol
Adv. 2024 Jul 29;6(1):vdae129. doi:
10.1093/noajnl/vdae129. PMID:
39211521. Interventional study.ˍ
Pichler J, Traub-Weidinger T, Spiegl K, Imamovic L, Braat AJAT,
Snijders TJ, Verhoeff JJC, Flamen P, Tauchmanova L, Hayward C,
Kluge A.
Results from a phase I study
of 4-L-[131I]iodo-phenylalanine
([131I]IPA)
with external radiation therapy in patients with recurrent
glioblastoma (IPAX-1).
Neurooncol
Adv. 2024 Jul 29;6(1):vdae130. doi:
10.1093/noajnl/vdae130. PMID:
39211520. Interventional study. ˍ
Tataranu LG, Staicu GA, Dricu A, Turliuc S, Paunescu D, Kamel A,
Rizea RE.
Combined Statistical Analysis
of Glioblastoma Outcomes-A Neurosurgical Single-Institution
Retrospective Study.
Medicina
(Kaunas). 2024 Jul 30;60(8):1234. doi:
10.3390/medicina60081234. PMID:
39202515. Observational study. ˍ
Biau J, Durando X, Boux F, Molnar I, Moreau J, Leyrat B, Guillemin
F, Lavielle A, Cremillieux Y, Seddik K, Dufort S, De Beaumont O,
Thivat E, Le Duc G.
NANO-GBM trial of
AGuIX nanoparticles with radiotherapy and temozolomide in the
treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and
MRI-based biodistribution.
Clin
Transl Radiat Oncol. 2024 Jul 31;48:100833. doi:
10.1016/j.ctro.2024.100833. PMID:
39184998. Interventional study. ˍ
Kurniawan T, Dwidanarti SR, Dhamiyati W, Ekaputra E, Meidania L,
Yanuarta SE, Choridah L.
Clinical
improvement of diffuse intrinsic pontine glioma treated with
radiation therapy concurrent with temozolomide: A case report.
Med
J Malaysia. 2024 Aug;79(Suppl 4):87-90. PMID:
39215422. Case report. ˍ
*Butler M, Mehra M, Chandasir A, Kaoutzani L, Vale FL.
Analysis
of the discontinuation and nonpublication of neurooncological
randomized clinical trials.
Neurooncol
Adv. 2024 Aug 1;6(1):vdae136. doi:
10.1093/noajnl/vdae136. PMID:
39211519. Observational study. ˍ
*Harter PN, Weber KJ, Ricklefs FL, Drexler R, Schüller U,
Hack M, Hanke T, Dohmen H, Acker T, von Deimling A, Hasselblatt M,
Divé I, Unger K, Steinbach JP, Capper D, Ronellenfitsch MW.
Survival probability of epigenetically
defined IDH-wild-type glioblastoma without necrosis or vascular
proliferation.
Neurooncol
Adv. 2024 Aug 2;6(1):vdae138. doi:
10.1093/noajnl/vdae138. PMID:
39184173. Observational study. ˍ
Cabezas-Camarero S, Pérez-Alfayate R, Polidura C,
Gómez-Ruiz MN, Gil-Martínez L, Casado-Fariñas
I, Bartolomé J, Pérez-Segura P.
Durable
benefit and slowdown in tumor growth dynamics with erdafitinib in
a FGFR3-TACC3 fusion-positive IDH-wild type
glioblastoma.
Neurooncol
Adv. 2024 Aug 6;6(1):vdae139. doi:
10.1093/noajnl/vdae139. PMID:
39211518. Case report. ˍ
Yang J, Lu J, Dong Y, Wei Y, Christian M, Huang J, Kuang H, Cao D.
Revealing the link between gut
microbiota and brain tumor risk: a new perspective from Mendelian
randomization.
Front
Cell Infect Microbiol. 2024 Aug 6;14:1404745. doi:
10.3389/fcimb.2024.1404745. PMID:
39165915. Observational study. ˍ
Di Nunno V, Gatto L, Tosoni A, Aprile M, Galvani L, Zappi A,
Foschini MP, Asioli S, Tallini G, De Biase D, Maloberti T,
Bartolini S, Giannini C, Franceschi E.
TP53
mutations and survival in patients with histologically defined
Glioblastoma, IDH-wildtype.
Pathol
Res Pract. 2024 Aug 8;262:155516. doi:
10.1016/j.prp.2024.155516. PMID:
39163733. Observational study˰
ˍ
Onishi S, Kojima M, Yamasaki F, Amatya VJ, Yonezawa U, Taguchi A,
Ozono I, Go Y, Takeshima Y, Hiyama E, Horie N.
T2-FLAIR
mismatch sign, an imaging biomarker for CDKN2A-intact in
non-enhancing astrocytoma, IDH-mutant.
Neurosurg
Rev. 2024 Aug 9;47(1):412. doi:
10.1007/s10143-024-02632-5. PMID:
39117984. Observational study. ˍ
Gheorghiu A, Brunborg C, Johannesen TB, Helseth E, Zwart JA,
Wiedmann MKH.
Lifestyle and metabolic
factors affect risk for meningioma in women: a prospective
population-based study (The Cohort of Norway).
Front
Oncol. 2024 Aug 12;14:1428142. doi:
10.3389/fonc.2024.1428142. PMID:
39188673. Observational study. ˍ
Kloosterman DJ, Erbani J, Boon M, Farber M, Handgraaf SM,
Ando-Kuri M, Sánchez-López E, Fontein B, Mertz M,
Nieuwland M, Liu NQ, Forn-Cuni G, van der Wel NN, Grootemaat AE,
Reinalda L, van Kasteren SI, de Wit E, Ruffell B, Snaar-Jagalska
E, Petrecca K, Brandsma D, Kros A, Giera M, Akkari L.
Macrophage-mediated myelin recycling
fuels brain cancer malignancy.
Cell.
2024 Aug 12:S0092-8674(24)00824-9. doi:
10.1016/j.cell.2024.07.030. PMID:
39137777. Laboratory investigation. ˍ
Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni
M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato
AM, Pancisi E, Foca F, D'Allagata M, Bondi I, Amadori E, Cortesi
P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini
D, Maimone G, Arpa D, Tosatto L.
First
step results from a phase II study of a dendritic cell vaccine in
glioblastoma patients (CombiG-vax).
Front
Immunol. 2024 Aug 13;15:1404861. doi:
10.3389/fimmu.2024.1404861. PMID:
39192978. Interventional study. ˍ
Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Reynolds ARN,
Fassinou ACR, Ayoub G, Lapinskas E, Pisano W, Jeang J, Stopka SA,
Regan MS, Spetz J, Desai A, Lieberman F, Fisher JD, Pelton K,
Huang RY, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S,
Walbert T, Ye X, Agar NYR, Grossman SA, Alexander BM, Wen PY,
Ligon KL, Beroukhim R.
Surgical window
of opportunity trial reveals
mechanisms of response and resistance
to navtemadlin (KRT-232) in patients with
recurrent glioblastoma.
medRxiv
[Preprint]. 2024 Aug 14:2024.08.12.24311893. doi:
10.1101/2024.08.12.24311893. PMID:
39211865. Interventional study. ˍ
Lee MD, Jain R, Galbraith K, Chen A, Lieberman E, Patel SH,
Placantonakis DG, Zagzag D, Barbaro M, Guillermo Prieto Eibl MDP,
Golfinos JG, Orringer DA, Snuderl M.
T2-FLAIR
Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B
Status in IDH-Mutant Astrocytomas.
Clin
Cancer Res. 2024 Aug 15;30(16):3512-3519. doi:
10.1158/1078-0432.CCR-24-0311. PMID:
38829583. Observational study˰
ˍ
Li W, Wang Z, Chen S, Liu Y.
Glioblastoma
concurrent with follicular lymphoma: A case report.
Asian
J Surg. 2024 Aug 20:S1015-9584(24)01715-9. doi:
10.1016/j.asjsur.2024.07.341. PMID:
39168739. Case report. ˍ
Soeung V, Puchalski RB, Noebels JL.
The
complex molecular epileptogenesis landscape of glioblastoma.
Cell
Rep Med. 2024 Aug 20;5(8):101691. doi:
10.1016/j.xcrm.2024.101691. PMID:
39168100. Laboratory investigation. ˍ